These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7964840)

  • 1. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
    Kempster PA; Lees AJ
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57(11):1444. PubMed ID: 7964840
    [No Abstract]   [Full Text] [Related]  

  • 2. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
    Rodriguez M; Lera G; Vaamonde J; Luquin MR; Obeso JA
    J Neurol Neurosurg Psychiatry; 1994 May; 57(5):562-6. PubMed ID: 8201324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor response to apomorphine in patients with Parkinson's disease with long-duration response to levodopa.
    Bonuccelli U; Napolitano A; Del Dotto P; Quattrone A
    Clin Neuropharmacol; 2002; 25(2):119-21. PubMed ID: 11981241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.
    Jenner P; Falup-Pecurariu C; Leta V; Verin M; Auffret M; Bhidayasiri R; Weiss D; Borovečki F; Jost WH
    J Neural Transm (Vienna); 2023 Nov; 130(11):1337-1347. PubMed ID: 37210460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    Neurology; 1998 Feb; 50(2):573-4. PubMed ID: 9484410
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
    Kempster PA; Frankel JP; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
    Djamshidian A; Poewe W
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S9-S12. PubMed ID: 28012951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Giuffra M; Conant K; Davis TL; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
    [No Abstract]   [Full Text] [Related]  

  • 12. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC; Burguera JA
    Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
    Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dopaminergic response in multiple system atrophy.
    Hughes AJ; Colosimo C; Kleedorfer B; Daniel SE; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1009-13. PubMed ID: 1469394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
    Sohn YH; Metman LV; Bravi D; Linfante I; Aotsuka A; Mouradian MM; Chase TN
    Neurology; 1994 Apr; 44(4):755-7. PubMed ID: 8164839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
    Corboy DL; Wagner ML; Sage JI
    Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
    Rascol OJ; Sabatini U; Chollet F; Montastruc JL; Marc-Vergnes JP; Rascol A
    Adv Neurol; 1993; 60():419-21. PubMed ID: 8420165
    [No Abstract]   [Full Text] [Related]  

  • 20. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.